This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diacon, A. H.
Right arrow Articles by Donald, P. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diacon, A. H.
Right arrow Articles by Donald, P. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2007, p. 2994-2996, Vol. 51, No. 8
0066-4804/07/$08.00+0     doi:10.1128/AAC.01474-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Early Bactericidal Activity of High-Dose Rifampin in Patients with Pulmonary Tuberculosis Evidenced by Positive Sputum Smears{triangledown}

A. H. Diacon,1* R. F. Patientia,2 A. Venter,3 P. D. van Helden,3 P. J. Smith,4 H. McIlleron,4 J. S. Maritz,5 and P. R. Donald6

Department of Internal Medicine,1 Department of Molecular Biology and Human Genetics and MRC Centre for Molecular and Cellular Biology, DST/NRF Centre of Excellence for Biomedical TB Research,3 Department of Paediatrics and Child Health, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, South Africa,6 Tiervlei Trial Centre, Karl Bremer Hospital, Bellville, South Africa,2 Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa,4 Biostatistics Unit of the South African Medical Research Council, Cape Town, South Africa5

Received 23 November 2006/ Returned for modification 26 March 2007/ Accepted 8 May 2007

We studied the early bactericidal activity of twice the standard dose of rifampin in subjects with pulmonary tuberculosis evidenced by positive smears. The observed mean 2-day activity was almost double that reported at the standard dose. Further studies are warranted to establish whether higher rifampin doses might assist in shortening tuberculosis treatment.

* Corresponding author. Mailing address: Department of Internal Medicine, Faculty of Health Sciences, University of Stellenbosch, P.O. Box 19063, 7505 Tygerberg, South Africa. Phone: 27 21 938 9556. Fax: 27 21 933 3591. E-mail: ahd{at}sun.ac.za

{triangledown} Published ahead of print on 21 May 2007.

Antimicrobial Agents and Chemotherapy, August 2007, p. 2994-2996, Vol. 51, No. 8
0066-4804/07/$08.00+0     doi:10.1128/AAC.01474-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Schon, T., Jureen, P., Giske, C. G., Chryssanthou, E., Sturegard, E., Werngren, J., Kahlmeter, G., Hoffner, S. E., Angeby, K. A. (2009). Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother 64: 786-793 [Abstract] [Full Text]  
  • Goutelle, S., Bourguignon, L., Maire, P. H., Van Guilder, M., Conte, J. E. Jr., Jelliffe, R. W. (2009). Population Modeling and Monte Carlo Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Rifampin in Lungs. Antimicrob. Agents Chemother. 53: 2974-2981 [Abstract] [Full Text]  
  • Barry, C. E. III (2009). Unorthodox Approach to the Development of a New Antituberculosis Therapy. NEJM 360: 2466-2467 [Full Text]  
  • van den Boogaard, J., Kibiki, G. S., Kisanga, E. R., Boeree, M. J., Aarnoutse, R. E. (2009). New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development. Antimicrob. Agents Chemother. 53: 849-862 [Full Text]  
  • Wilkins, J. J., Savic, R. M., Karlsson, M. O., Langdon, G., McIlleron, H., Pillai, G., Smith, P. J., Simonsson, U. S. H. (2008). Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients, Including a Semimechanistic Model To Describe Variable Absorption. Antimicrob. Agents Chemother. 52: 2138-2148 [Abstract] [Full Text]  
  • McIlleron, H., Norman, J., Kanyok, T. P., Fourie, P. B., Horton, J., Smith, P. J. (2007). Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers. J Antimicrob Chemother 60: 1398-1401 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»